Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...

A radical plan by a former Trump aide seeks to encourage obese Americans to lose weight—by helping their wallet. Robert P.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion.

Only 13 states provide coverage under Medicaid for weight loss purposes. To make them more accessible, then-President Joe Biden recently proposed that Medicare and Medicaid cover them, but now that ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to higher prices for popular weight-loss drugs Ozempic and Wegovy as well ...

AdvaMed, the largest medical device association globally, urged the Trump administration to exempt medical products from the ...